

NORWAY

Decision-Making

Stakeholders: Norwegian Institute of Public Health (NIPH), National Immunisation Technical Advisory Group (NITAG), Ministry of Health and Care Services.

Introducing a new vaccination: NITAG reviews horizon scanning reports to identify emerging vaccines and technologies, assessing their relevance to national health needs. They make recommendations to the NIPH, which decides what to submit to the Ministry of Health and Care Services. The decision-making considers innovative approaches, with tenders often weighing factors like quality (up to 60%) and price (40%). While funding for innovative methods is generally limited, the system signals an openness to recognising the value of new vaccines through this quality/price tendering model.

Financing

Primary Funding Sources: The government health budget ensures vaccines are accessible to targeted groups.

Sustainability: Yes. Long-term tenders (4 years +)

Critical Financing Challenges: Significant bureaucratic hurdles.


	Yes	No
Ministry of Finance Involvement		✓
Ringfencing		✓
Financial Mechanisms for Sustainability	✓	
External Funding Sources		✓
Influence of Public-Private Partnerships		✓

Landscape

History of Vaccination: Norway's vaccine program traditionally funds vaccines included in the paediatric program. Norway's robust healthcare system emphasises preventive care and provides free vaccines to high-risk groups, including children, pregnant women, and individuals with chronic conditions. The high public trust in healthcare professionals further enhances vaccine uptake nationwide.

Most Funded Campaign: The paediatric vaccination program

Future: Funding for COVID-19 vaccines is anticipated to continue, with potential funding expansions to include flu and pneumococcal vaccines for risk groups.



Decentralised Health System



7.9%
of GDP spent
on healthcare



2.7%
of healthcare
budget is spent
on prevention



63.3%
Over-65 influenza
vaccination
coverage (2022)

Adult vaccination (18+) recommendation against 7 diseases:

COVID-19*
Diphtheria*
Tetanus*
Pertussis*
Poliomyelitis*
Influenza*
Pneumococcal disease

*6/7 are government funded

